Hypertension-Mediated Organ Damage (HMOD)
Definition
Hypertension-mediated organ damage (HMOD) refers to structural and functional changes in target organs (heart, kidney, arteries, eye, brain) caused by persistently elevated blood pressure. HMOD indicates long-standing hypertension and confers incremental prognostic CVD risk beyond BP level and traditional risk factors alone. In the ESC 2024 framework, evidence of HMOD in a patient with elevated BP (SBP 120–139 mmHg) automatically classifies them as sufficiently high CVD risk to warrant BP-lowering treatment — without needing to calculate SCORE2. (sources/ht-esc-2024, rating: very high)
Key Concepts
Why HMOD Matters Clinically
- HMOD provides incremental CVD risk stratification above and beyond BP level alone (sources/ht-esc-2024, rating: very high)
- Three uses in ESC 2024 framework:
- Triggers BP-lowering treatment for elevated BP (120–139/70–89 mmHg) patients — equivalent to high CVD risk conditions such as CKD or established CVD
- Guides therapy intensification — persistent or worsening HMOD despite treatment predicts worse outcomes even if BP is at target
- Overcomes therapeutic inertia — visual evidence of organ damage motivates patients and physicians to achieve treatment targets
Renal HMOD — Assessment and Thresholds
All hypertensive patients should have renal HMOD assessed (Class I, A): (sources/ht-esc-2024, rating: very high)
| Marker | HMOD Threshold |
|---|---|
| eGFR | <60 mL/min/1.73 m² (irrespective of albuminuria) |
| Albuminuria (ACR) | ≥30 mg/g or ≥3 mg/mmol (irrespective of eGFR) |
- Routine tests: serum creatinine + race-free CKD-EPI eGFR + urinary ACR at first assessment
- If moderate-to-severe CKD: repeat eGFR and ACR at least annually (Class I, C)
- Renal ultrasound + Doppler should be considered in hypertensive CKD to assess structure and exclude renovascular causes (Class IIa, C)
Cardiac HMOD — ECG
12-lead ECG is mandatory for all patients with hypertension (Class I, B): (sources/ht-esc-2024, rating: very high)
LVH criteria (ECG):
- Sokolow-Lyon: SV1 + RV5 >35 mm
- RaVL ≥11 mm
- Cornell voltage: SV3 + RaVL >28 mm (men) or >20 mm (women)
- Cornell voltage-duration product also applicable
Other ECG uses: detection of AF, prior myocardial infarction, LA enlargement (PTF-V1)
Cardiac HMOD — Echocardiography
Echocardiography recommended if ECG abnormal or cardiac symptoms (Class I, B); may be considered in elevated BP when likely to change management (Class IIb, B): (sources/ht-esc-2024, rating: very high)
LVH thresholds (sex-specific):
| Parameter | Men | Women |
|---|---|---|
| LV mass/height²·⁷ | >50 g/m²·⁷ | >47 g/m²·⁷ |
| LV mass/BSA | >115 g/m² | >95 g/m² |
| RWT (concentric geometry) | ≥0.43 | ≥0.43 |
LA enlargement:
| Parameter | Men | Women |
|---|---|---|
| LA volume/height² | >18.5 mL/m² | >16.5 mL/m² |
| LA volume index | >34 mL/m² | >34 mL/m² |
Diastolic dysfunction: e' <7 cm/s; E/e' >14
Cardiac HMOD — Biomarkers
High-sensitivity troponin and NT-proBNP are HMOD markers (and also risk modifiers in the borderline CVD risk zone): (sources/ht-esc-2024, rating: very high)
- hs-cTnT or hs-cTnI: >99th percentile upper reference limit
- NT-proBNP: >125 pg/mL if age <75 years; >450 pg/mL if age ≥75 years
Vascular HMOD — Arteries
All vascular HMOD assessments are Class IIb (may be considered when likely to change management): (sources/ht-esc-2024, rating: very high)
| Test | HMOD Threshold |
|---|---|
| Carotid-femoral PWV | >10 m/s |
| Brachial-ankle PWV | >14 m/s |
| Carotid or femoral plaque | Focal wall thickness >1.5 mm |
| Coronary artery calcium (CAC) | >100 Agatston units |
- Inter-arm SBP difference >10 mmHg: suspect arterial stenosis (subclavian) as vascular HMOD
- ABI and abdominal ultrasound if peripheral artery disease or aortic aneurysm suspected
Microvascular HMOD — Fundoscopy
- Recommended if BP >180/110 mmHg (hypertensive emergency work-up) or in hypertensive diabetic patients (Class I, C)
- May be considered in elevated BP/hypertension (Class IIb, B)
- Mild or moderate hypertensive retinopathy associated with increased CVD event risk in hypertensive patients
- White matter lesions and silent microinfarcts on brain MRI are also HMOD markers but assessed less routinely
Practical HMOD Assessment Framework (ESC 2024)
When to assess HMOD — four priority indications:
- Elevated BP (120–139/70–89 mmHg) with SCORE2 risk 5–<10% — HMOD positive result → triggers treatment
- Uncertain situations (BP or risk near thresholds, masked/white-coat hypertension)
- Non-traditional CVD risk factor setting where additional risk information is needed
- Patients <40 years old with elevated BP (SCORE2 not validated; HMOD is the preferred stratification tool)
Contradictions / Open Questions
- HMOD regression as surrogate: Whether regression of HMOD (e.g., LVH on treatment) translates into equivalent CVD event reduction is not established by RCTs; HMOD trials use surrogate endpoints (sources/ht-esc-2024, rating: very high)
- Sex-specific echo thresholds: Sex-specific LVH thresholds recognised in ESC 2024 but derived from observational data; validation in prospective outcome trials limited
- Cardiac biomarkers as HMOD: hs-cTnT/NT-proBNP can reflect atherosclerosis or arrhythmia (not only hypertensive damage); therefore listed in both HMOD and risk modifier categories — clinical interpretation context-dependent
- Fundoscopy underutilised: Hypertensive retinopathy grading provides prognostic information but fundoscopy is infrequently performed in routine hypertension care
- Brain HMOD: White matter lesions/lacunar infarcts on MRI are recognised HMOD but MRI not routinely recommended — practical assessment gap
Connections
- Related to entities/Hypertension — HMOD triggers treatment decisions in the elevated BP category
- Related to concepts/ECG-Ventricular-Hypertrophy — LVH criteria used in HMOD assessment
- Related to concepts/LV-Diastolic-Function — diastolic dysfunction as cardiac HMOD marker
- Related to concepts/Blood-Pressure-Target-T2DM — CKD (renal HMOD) automatically qualifies for treatment